


EMPA-HEART CardioLink-6 Trial

Discussant

Elliott Antman, MD

Brigham and Women's Hospital, Boston, MA



T2DM



Improved glycemia
Weight loss

SGLT2i

Delayed decline in eGFR
Delayed albuminuria



⇓⇓ HF hosp

Primary Outcome

Empagliflozin Reduces LVMI^a


Baseline LVMI^a
(g/m²)

62.2

59.5

Placebo

Empagliflozin



LVM regression (g)

-0.39 (10.83)


-4.71 (15.43)



Exploratory Analyses

Relationship between LVM*, BP and Hematocrit


“Afterload”



Mean Systolic BP (mmHg)

PCC 0.34

“Preload”




Hematocrit

PCC -0.20



T2DM





Improved glycemia
Weight loss



Improved myocardial bioenergetics
Effect on NHE

SGLT2i

Delayed decline in eGFR
Delayed albuminuria



preload ✓

afterload ✓

epicardial
adipose tissue

